» Articles » PMID: 33469997

Bisphenol A at a Human Exposed Level Can Promote Epithelial-mesenchymal Transition in Papillary Thyroid Carcinoma Harbouring BRAF Mutation

Overview
Journal J Cell Mol Med
Date 2021 Jan 20
PMID 33469997
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

Bisphenol A (BPA), a ubiquitous endocrine-disrupting chemical, alters the function of endocrine system and enhances the susceptibility to tumorigenesis in several hormone-dependent tumours as thyroid carcinoma. About 50% of papillary thyroid cancers (PTC), the most common type of thyroid malignancy, harbours the BRAF mutation. This study aimed to investigate a potential combined effect of BPA exposure and BRAF mutation on epithelial-mesenchymal transition (EMT) in PTC. Firstly, the level of BPA in plasma, the evaluation of BRAF mutation and the level of EMT-related proteins in PTC samples were individually determined. Additionally, the migration, invasion, colony formation capacity and the expression of EMT-related proteins after exposure to BPA were precisely analysed in vitro thyroid cells genetically modified by the introduction of BRAF mutation. Moreover, ERK-Cox2 signalling pathway was also introduced to explore the possible mechanism in PTC development. As expected, whether the clinical investigation or cultured thyroid cells demonstrated that BPA at a concentration compatible with human exposed levels (10  M) synergized with the BRAF mutation promoted EMT via the activation of ERK-Cox2 signalling pathway. Our findings offer some evidence that BPA as an environmental risk factor can facilitate the progression of PTC harbouring BRAF mutation.

Citing Articles

Environmental Exposure to Bisphenol A Enhances Invasiveness in Papillary Thyroid Cancer.

Huang C, Xie R, Li P, Chen C, You B, Sun Y Int J Mol Sci. 2025; 26(2).

PMID: 39859529 PMC: 11766120. DOI: 10.3390/ijms26020814.


Current Evidence on Bisphenol A Exposure and the Molecular Mechanism Involved in Related Pathological Conditions.

Della Rocca Y, Traini E, Diomede F, Fonticoli L, Trubiani O, Paganelli A Pharmaceutics. 2023; 15(3).

PMID: 36986769 PMC: 10053246. DOI: 10.3390/pharmaceutics15030908.


Alternation between toxic and proliferative effects of Roundup® on human thyroid cells at different concentrations.

Dal Bo I, Teixeira E, Rabi L, Peres K, Nascimento M, Chiamolera M Front Endocrinol (Lausanne). 2022; 13:904437.

PMID: 35992109 PMC: 9382701. DOI: 10.3389/fendo.2022.904437.


Identification and Validation of Prognostic Related Hallmark ATP-Binding Cassette Transporters Associated With Immune Cell Infiltration Patterns in Thyroid Carcinoma.

Wang L, Sun X, He J, Liu Z Front Oncol. 2022; 12:781686.

PMID: 35837087 PMC: 9273952. DOI: 10.3389/fonc.2022.781686.


Sex Bias in Differentiated Thyroid Cancer.

Suteau V, Munier M, Briet C, Rodien P Int J Mol Sci. 2021; 22(23).

PMID: 34884794 PMC: 8657786. DOI: 10.3390/ijms222312992.


References
1.
Cohen Y, Xing M, Mambo E, Guo Z, Wu G, Trink B . BRAF mutation in papillary thyroid carcinoma. J Natl Cancer Inst. 2003; 95(8):625-7. DOI: 10.1093/jnci/95.8.625. View

2.
Bahrami A, Majeed M, Sahebkar A . Curcumin: a potent agent to reverse epithelial-to-mesenchymal transition. Cell Oncol (Dordr). 2019; 42(4):405-421. DOI: 10.1007/s13402-019-00442-2. View

3.
Lee Y, Ryu H, Kim H, Min C, Lee J, Kim E . Maternal and fetal exposure to bisphenol A in Korea. Reprod Toxicol. 2008; 25(4):413-9. DOI: 10.1016/j.reprotox.2008.05.058. View

4.
Kim J, Seong C, Bae I, Yi J, Yu H, Kim S . Comparison of Immunohistochemistry and Direct Sequencing Methods for Identification of the BRAF Mutation in Papillary Thyroid Carcinoma. Ann Surg Oncol. 2018; 25(6):1775-1781. DOI: 10.1245/s10434-018-6460-3. View

5.
Li L, Li H, Zhang J, Gao X, Jin H, Liu R . Bisphenol A at a human exposed level can promote epithelial-mesenchymal transition in papillary thyroid carcinoma harbouring BRAF mutation. J Cell Mol Med. 2021; 25(3):1739-1749. PMC: 7875916. DOI: 10.1111/jcmm.16279. View